^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report

Published date:
05/26/2020
Excerpt:
In this case report, we describe a patient with EML4-ALK-rearranged stage IIIB MPM who was administered with alectinib and lorlatinib as first-line and fourth-line therapy, respectively....Sequencing analysis revealed the emergence of ALK I1171N and L1196M at alectinib progression.
DOI:
10.1177/1753466620935770